Building AI Agents for Life Sciences: From Silos to Synthesis

TL;DR:

• AI agents unify fragmented clinical trial data across sponsor, CRO, site, and lab systems into actionable intelligence.
• Automated site selection, feasibility assessment, and patient matching accelerate trial timelines by six months or more.
• Real-world data integration enables predictive protocol design and enrollment forecasting before trial activation.
• Agentic systems reason autonomously over domain rules, regulatory constraints, and operational workflows to reduce manual overhead.
• Integration success depends on data standardization, explainability for regulators, and human oversight in clinical decisions.

Introduction

Life sciences organizations operate across disconnected ecosystems. Sponsors, contract research organizations (CROs), clinical sites, laboratories, and patient data repositories exist in separate silos. Clinical trials rely on data collection from multiple sources including sites, patients, and labs, with data coming from different systems and multiple vendors, and review and analysis carried out by multiple stakeholders at the CRO and sponsor. AI will deliver return on investment in 2026 by slashing costly clinical trial missteps through simulation, made possible by increases in data collection and centralisation. The emergence of custom AI agents designed to operate within existing workflows represents a fundamental shift in how life sciences teams can synthesize data, accelerate decision-making, and reduce operational friction without replacing human expertise.

What Are AI Agents in Life Sciences Operations?

An AI agent in life sciences is an autonomous system that reasons over structured and unstructured data, applies domain rules and regulatory constraints, and executes multi-step workflows to accomplish specific operational objectives. Unlike static models or chatbots, agents continuously observe trial state, adapt to new information, and take action across integrated systems.

• Agents integrate data from electronic data capture (EDC) systems, electronic health records (EHRs), claims databases, and real-world data repositories.
• They apply clinical, operational, and regulatory logic to rank sites, predict enrollment, flag protocol risks, and optimize resource allocation.
• Agents operate within existing systems using native APIs and workflows, not as external tools that require manual handoff.
• Agentic AI represents the next evolution beyond traditional automation, with systems that not only perform tasks but can also plan, reason, and make autonomous decisions based on real-time data, accelerating the shift from reactive to proactive data management.
• Human experts retain validation authority; agents surface recommendations with transparent reasoning and evidence.

The Core Problem: Data Fragmentation and Manual Bottlenecks

The complexity of clinical trials has surged dramatically, with Phase 3 trials seeing a 39% increase in countries since 2015, trials now involve more investigator sites and more protocol amendments, and the push for greater patient diversity necessitates deeper understanding of patient populations, resulting in unplanned delays and unforeseen costs.

• Clinical research systems use a multitude of eClinical systems that need to communicate with each other, with interoperability challenges between healthcare systems (EHR/EMR) and clinical trial systems (EDCs).
• ClinOps teams are still contending with the overarching burden of manual processes that persist during investigator site selection, and embracing automation and streamlining site selection workflows could significantly reduce costs and accelerate study timelines.
• The investigator site selection process begins with feasibility questionnaires, but each CRO or sponsor has its own unique format for these questionnaires, leading to a lack of standardization across the industry.
• Sponsors and CROs often do not digitize and store the data they have collected from site feasibility questionnaires, even when information is digitized it remains unsearchable because key terminologies aren't linked in a machine-readable way, making it almost impossible for ClinOps teams to search past questionnaires to accelerate the site selection of new protocols.
• A common challenge in site selection strategies is aggregating the information collected to make final decisions, and the range of variables that impact site performance require an effective measurement of the trade-offs that influence prospective recruitment performance.

How AI Agents Transform Site Selection and Feasibility

Site selection is the first critical gate in trial execution. Poor selection cascades into enrollment delays, protocol deviations, and data quality issues. AI agents convert this manual, fragmented process into a data-driven, continuously updated decision system.

Unified Data Ingestion

• Agents ingest historical site performance metrics, investigator qualifications, patient demographics, and infrastructure capabilities from internal databases.
• RWD enables streamlined feasibility assessments during protocol design, with sponsors assessing the likelihood of enrolling enough patients by analyzing data from EHRs and claims databases, reducing the risk of under-enrollment, a common challenge that can delay trial completion and increase costs.
• External data sources (epidemiology, claims, wearables) are normalized and mapped to standardized ontologies so terminology mismatches no longer block retrieval.
• Agents maintain a unified patient pool view across regions, indications, and data sources in real-time.

Predictive Enrollment Forecasting

• Machine learning approaches outperform baseline methods to rank research sites based on their expected recruitment in future studies, using indication level historical recruitment and real-world data to predict patient enrollment at site level.
• By incorporating AI technologies like machine learning into RWD, researchers can gain significantly deeper insights, with ML-trained predictive models analyzing diverse RWD to identify clinical patterns indicative of candidate eligibility, and these patterns informing a scoring algorithm that assesses participant pools both now and in the future.
• Agents compute site-specific enrollment curves, flag capacity constraints, and recommend protocol adjustments before trial activation.
• Organizations can test assumptions, evaluate multiple scenarios, and expose bottlenecks long before they turn into delays, eligibility criteria can be stress-tested, enrolment curves can be predicted, and more molecules can be disqualified in Phase I and II before the more expensive Phase III trials, reducing development timelines for trials by at least six months.

Automated Feasibility Assessment

• Agents parse feasibility questionnaires, map responses to standardized data models, and flag inconsistencies or missing information automatically.
• They compare site capabilities against protocol requirements (equipment, staffing, regulatory certifications, patient access) and surface mismatches with confidence scores.
• Past research experience, past high research performance and a high number of patients are consistently strong positive indicators of recruitment potential.
• Agents enable site comparison across multiple dimensions simultaneously, reducing subjective decision-making.

Comparison of Traditional vs. AI-Agent-Driven Site Selection

Integration with Real-World Data and Protocol Design

Clinical, operational, and real-world data will be used together, which will reshape the foundations of trial design and execution, as sponsors have relied on retrospective analyses, intuition, and fragmented feasibility insights to design protocols, but with increased use of wearables and other digital data collection assets and the ability of AI to analyse and simulate, the volume and richness of today's data now make a new approach possible.

• Agents analyze multi-omics data, genomics, wearable signals, and EHR records to identify patient subpopulations that match trial eligibility criteria.
• By analyzing large and diverse patient populations, researchers can gain insights into disease epidemiology, treatment patterns, and unmet needs across different demographic groups, and these insights can inform the development of eligibility criteria that are more inclusive and reflective of the patient populations seen in clinical practice.
• Agents support adaptive trial design by continuously monitoring enrollment against predictions and recommending protocol adjustments or site rebalancing.
• AI is unlocking new possibilities by integrating multi-omics data with clinical records, resulting in greater insight into patterns, breakthroughs in predictive biomarkers, and smarter patient stratification, improving the effectiveness of treatments.

Regulatory and Governance Considerations

Regulatory authorities are continuing to be dissatisfied with black box results, and rather want traceable, explainable logic and robust data provenance for every clinical decision made or supported by AI.

• A defining development of 2025 was AI's increasing proximity to decisions with regulatory implications, especially when AI is used to generate information intended to support assessments of safety, effectiveness, or quality, and in January 2025, the FDA published draft guidance outlining a risk-based credibility assessment framework for AI models used in this context, emphasizing context of use and ongoing performance evaluation.
• In 2026, there will be a shift from the use of copilots as only code assistants to take on automation of manual tasks and accelerate drug submission approvals, and AI agents take on a bigger role in 2026, but humans will still be engaged to validate and approve agent output.
• Agents must maintain audit trails documenting which data sources informed each decision, how models were trained, and what thresholds triggered recommendations.
• Targeted use of AI will continue to grow – especially in feasibility, site selection, recruitment, and operational risk prediction – but under much stricter governance as regulators and legal frameworks bite.
• Organizations must establish governance frameworks defining when agent recommendations require human approval before execution.

Practical Implementation: Workflow Integration

AI agents operate most effectively when embedded into existing workflows rather than deployed as standalone tools. This requires alignment with CRO and sponsor systems, data governance policies, and clinical operations teams.

Data Standardization Foundation

• Ontologies create human-generated, machine-readable descriptions of a domain, which broadly consists of types of things and the relationships between them, and applying ontologies to standardize and structure site selection data would create a community consensus view of the domain that is updated as the field evolves.
• Agents require consistent naming conventions, field mappings, and data quality rules across all source systems.
• Sponsors and CROs must invest in master data management before deploying agents at scale.

Integration Points

• Agents connect to EDC systems via APIs to retrieve case report form data and protocol deviations in real-time.
• They read from EHR systems (with appropriate privacy controls) to assess patient eligibility and site capacity.
• Agents feed recommendations into clinical trial management systems (CTMS) and supply chain forecasting tools.
• Output dashboards surface agent reasoning to ClinOps teams, enabling rapid review and decision-making.

Human-in-the-Loop Governance

• Agents recommend site rankings, enrollment forecasts, and protocol adjustments but do not execute decisions unilaterally.
• Clinical operations leaders review agent recommendations, validate against domain knowledge, and approve or override before action.
• Agents log all recommendations, approvals, and overrides for regulatory audit and continuous improvement.

Common Pitfalls and Constraints

• The absence of large-scale linkage between claims data and electronic healthcare records, lab, and genomic data, poses challenges in the replication of study cohorts.
• While expected recruitment is an important consideration in site selection strategies, it should not be the sole determinant in trial planning, and other factors, such as the overall experience collaborating with a research site and their research capabilities must also be considered, and sites with a diverse patient population need to be considered to improve the representativeness of the study population of clinical trials.
• In 2026, one of the biggest challenges facing the life sciences industry will be navigating a growing divergence in regulatory approaches across countries, and increasingly, regulators are mandating that clinical data must remain in the country where it was collected, which fundamentally disrupts centralised data strategies that have long supported efficient trial design, creating operational friction.
• Agents trained on historical data may perpetuate bias if training sets underrepresent diverse patient populations or underperforming sites with high potential.
• Data quality issues in source systems (missing values, inconsistent coding) degrade agent performance; garbage in, garbage out remains a hard constraint.

Why Integrated AI Agents Outperform Point Solutions

The life sciences industry has deployed isolated AI tools for patient matching, site scoring, or protocol simulation. These tools produce value but remain disconnected from operational workflows, requiring manual data export, re-entry, and reconciliation. Integrated agents solve a different problem: they synthesize insights across the entire trial lifecycle and embed recommendations into the systems clinicians already use.

• Point solutions require manual handoff; agents operate continuously within existing systems.
• Point solutions optimize single dimensions (e.g., enrollment); agents balance multiple objectives (enrollment, diversity, data quality, cost).
• Point solutions require retraining for each new trial; agents leverage institutional knowledge and adapt to new data in real-time.
• Integrated agents reduce organizational friction by eliminating the need for new software, training, or workflow redesign.

Organizations like Pop focus on building custom AI agents for teams overwhelmed with manual work and disconnected tools. Machine learning and cloud-native platforms will be central to life sciences R&D, minimizing clinical trial failures and accelerating regulatory approvals, and AI-driven drug discovery will shorten timelines for identifying viable drug candidates, while decentralized trials will play a pivotal role in reshaping study design and patient access. Pop designs agents that operate inside existing systems, using proprietary data, rules, and workflows to take ownership of real work. Rather than adding another software license, Pop's approach focuses on tailored execution: start with one high-impact problem, prove value quickly, and scale only what moves the business forward. The result is practical AI that reduces friction, improves productivity, and helps life sciences teams operate at a much larger scale.

Strategic Perspective: When and How to Deploy AI Agents

Not every life sciences operation should deploy AI agents immediately. The decision hinges on data maturity, governance readiness, and problem severity.

• Success in 2026 will depend on systems thinking, with teams needing strong data foundations, clear validation practices, and collaboration across biology, engineering, and quality functions.
• A sharp divide is emerging between organizations building AI fluency into every layer of the clinical process and legacy operators still piloting stand-alone AI use cases, and by 2026, that gap will dictate survival, with an organization's AI fluency, measured in talent, governance, and operational agility, becoming its number one differentiator.
• Organizations with fragmented data sources, high manual overhead in site selection, or frequent enrollment delays are prime candidates.
• Organizations with immature data governance, inconsistent terminology, or weak change management should invest in data standardization first.
• Agents deliver highest ROI when deployed against high-volume, repetitive tasks with clear decision criteria (site selection, feasibility assessment, enrollment forecasting).

Key Takeaway on AI Agents in Life Sciences

• AI agents unify fragmented trial data and automate feasibility assessment, site selection, and enrollment forecasting, reducing timelines by six months or more.
• Agents reason over real-world data, regulatory constraints, and operational rules to surface proactive recommendations while maintaining human oversight.
• Success requires data standardization, explainable decision logic, and integration with existing clinical trial management systems.
• Organizations that embed AI fluency into core clinical processes will outpace those piloting isolated use cases.
• Regulatory frameworks now demand transparent, auditable AI decisions; agents must log reasoning, data provenance, and human approvals.

Ready to Transform Trial Operations with AI?

Building custom AI agents requires more than algorithms; it demands deep understanding of clinical workflows, regulatory constraints, and organizational data. Teams ready to move beyond pilot projects and integrate AI into core operations should evaluate solutions that embed agents directly into existing systems. Visit Pop to explore how tailored AI agents can reduce manual overhead in site selection, feasibility assessment, and trial planning, enabling your team to focus on strategy and patient outcomes.

FAQs

Question 1: How do AI agents differ from traditional AI tools in clinical trials?

Traditional tools optimize single dimensions (patient matching or site scoring). AI agents reason across multiple data sources and objectives simultaneously, operate continuously within existing systems, and adapt recommendations based on real-time trial state. Agents maintain audit trails and integrate human approval gates, whereas point tools require manual handoff and re-entry.

Question 2: What data sources do AI agents integrate for site selection?

Agents ingest internal site performance metrics, investigator qualifications, and infrastructure data; external real-world data from EHRs, claims databases, and epidemiology registries; and historical enrollment data from prior trials. They normalize and map this data to standardized ontologies so terminology mismatches no longer block retrieval or comparison.

Question 3: How much faster is trial execution with AI agents?

Organizations using AI-driven site selection and feasibility assessment report site activation in 2-3 weeks versus 4-8 weeks with manual processes. Predictive enrollment modeling enables protocol stress-testing before trial launch, reducing costly amendments. Overall development timelines can shorten by six months or more when agents inform adaptive trial design.

Question 4: What regulatory approvals are required to deploy AI agents in clinical trials?

The FDA and EU AI Act require explainable decision logic, documented model training and validation, and audit trails showing data provenance and human approval gates. Agents used to generate information supporting regulatory decisions must meet risk-based credibility standards. Most operational agents (site selection, feasibility assessment) do not require pre-approval but must maintain governance frameworks and transparent reasoning.

Question 5: How do organizations ensure AI agents do not perpetuate bias in site or patient selection?

Agents must be trained on diverse, representative data sets and validated across patient subpopulations and geographic regions. Organizations should monitor agent recommendations for demographic disparities and conduct regular audits of site diversity and enrollment patterns. Human review gates allow clinical teams to override agent recommendations when bias or fairness concerns emerge.

Question 6: What is the first step to implement AI agents in a life sciences organization?

Assess data maturity: inventory source systems, evaluate data quality and standardization, and identify the highest-impact manual bottleneck (site selection, feasibility, enrollment forecasting). Organizations with fragmented data should invest in master data management and ontology development first. Then pilot an agent on a single high-volume problem and measure time savings and decision quality before scaling.

‍